Gestational Age at Enrollment and Continued Substance Use Among Pregnant Women in Drug Treatment

Substance use during pregnancy is associated with poor obstetrical and neonatal outcomes. Although intervention for substance use including alcohol improves pregnancy outcomes, a substantial number of women continue to use drugs or consume alcohol during treatment. To determine whether gestational age at entry into treatment (specifically first trimester enrollment) was associated with lower risk of continued substance use, we analyzed the North Carolina Treatment Outcomes and Program Performance System, an administrative database of drug treatment clinics, between 2000 and 2004. There were 847 pregnant women using substances who met our inclusion criteria. Demographic and other risk factor data were collected. We conducted logistic regression and a Generalized Estimating Equation analysis. Gestational age at enrollment was not associated with continued substance use (odds ratio [OR] = 0.88; 95% confidence interval [CI] = 0.51, 1.51). Women who had child care provided, were less likely to continue substance use (OR = 0.64; 95% CI = 0.48, 0.84), whereas those referred from the criminal justice system were more likely to continue (OR = 1.53; 95% CI = 1.01, 2.30). Although earlier gestational age at enrollment in treatment does not predict greater abstinence at any time point, this data does suggest that the provision of childcare may improve treatment success

Perspective on post-menopausal osteoporosis: establishing an interdisciplinary understanding of the sequence of events from the molecular level to whole bone fractures

Current drug treatments for post-menopausal osteoporosis cannot eliminate bone fractures, possibly because the mechanisms responsible for bone loss are not fully understood. Although research within various disciplines has significantly advanced the state of knowledge, fundamental findings are not widely understood between different disciplines. For that reason, this paper presents noteworthy experimental findings from discrete disciplines focusing on post-menopausal osteoporosis. These studies have established that, in addition to bone loss, significant changes in bone micro-architecture, tissue composition and micro-damage occur. Cellular processes and molecular signalling pathways governing pathological bone resorption have been identified to a certain extent. Ongoing studies endeavour to determine how such changes are initiated at the onset of oestrogen deficiency. It emerges that, because of the discrete nature of previous research studies, the sequence of events that lead to bone fracture is not fully understood. In this paper, two sequences of multi-scale changes are proposed and the experimental challenges that need to be overcome to fully define this sequence are outlined. Future studies must comprehensively characterize the time sequence of molecular-, cellular- and tissue-level changes to attain a coherent understanding of the events that ultimately lead to bone fracture and inform the future development of treatments for post-menopausal osteoporosis

Smallpox vaccine program 2002–2016 date of immunization: Vaccine Adverse Event Reporting System (VAERS) data available with iterative database searches ldentifying subsets of cases with new onset cardiac symptoms and then meeting the 2003 epidemiologic case definition for myocarditis/pericarditis.

Box 1: Vaccination Dates: Dec 2002–2016: Data Source: CDC/FDA VAERS Database using CDC Wonder Search tool. Accessed June 2020. https://wonder.cdc.gov. Box 2: Cardiac Symptoms/Diagnoses by MedDRA Terms (see S1 Table): All Ages, Locations, No Limits (1081) = then Limit Symptom Onset Day 1–60 = then Limit to Military. Box 3: Final Cohort of myocarditis and pericarditis with smallpox vaccine association using CDC case definitions (2003: See Table 1). Box 4a and 4b (left to right): Myocarditis and Pericarditis cases detailed by level of certainty for diagnostic accuracy based on criteria in CDC case definitions with no other etiology identified.</p